

An FDA Perspective on FDA Atypical Active Ingredients (On-Demand)

Art. ID	USP-EXC-ESF-02
Unit	Each
Deliverydetails	No Dangerous Good

Description

This presentation from the USP Excipient Stakeholder Forum summarizes the FDA's current positions on atypical actives, covering issues with GMP, specification and labeling. Examples are presented, including a discussion of responsibilities and challenges ahead (Webcast 22 minutes)